<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01420341</url>
  </required_header>
  <id_info>
    <org_study_id>HE541074</org_study_id>
    <nct_id>NCT01420341</nct_id>
  </id_info>
  <brief_title>Co-trimoxazole as Maintenance Therapy for Meliodosis</brief_title>
  <official_title>A Comparison Between 12 vs. 20 Weeks of Co-trimoxazole as Maintenance Therapy for Melioidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, open-labelled, controlled trial to compare the efficacy and
      effectiveness on relapse-free rate of 12-week versus 20-week oral eradication treatment of
      melioidosis. The study population includes 800 patients with culture-confirmed melioidosis
      whom 12 weeks of oral eradication therapy have been completed with or without intravenous
      intensive antibiotics. Patients will be randomised to either stop the eradication treatment
      or continue current oral treatment for 8 more weeks. The study aim to optimise the regimen
      used to treat melioidosis for better compliance and reducing unnecessary use of antibiotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Planed interim analysis will be conducted when the patient enrollment reaches 600 cases for
      evaluating safety and futility of the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year non relapse rate</measure>
    <time_frame>1 year</time_frame>
    <description>This is defined as clinical features of meliodosis after initial improvement, in association with cultures from any site positive for Burkhoderia pseudomallei. This can be any time point during or after stopping antibiotic treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Recurrence</measure>
    <time_frame>1 year</time_frame>
    <description>Recurrent clinical features of meliodosis treated as such but not confirmed by positive culture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>9 weeks</time_frame>
    <description>Clinical decision to change treatment according to inadequate response to therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Drug Reactions</measure>
    <time_frame>9 weeks</time_frame>
    <description>Adverse events that are caused by the drug including drug allergy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug compliance</measure>
    <time_frame>12 or 20 weeks</time_frame>
    <description>This will be done by interviewing and pill counting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Meliodosis</condition>
  <arm_group>
    <arm_group_label>Co-trimoxazole 12</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receive treatment with co-trimoxazole for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Co-trimoxazole 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receive treatment with co-trimoxazole for 20 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Co-trimoxazole 12</intervention_name>
    <description>Receive treatment with co-trimoxazole for 12 weeks.</description>
    <arm_group_label>Co-trimoxazole 12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Co-trimoxazole 20</intervention_name>
    <description>Receive treatment with co-trimoxazole for 20 weeks.</description>
    <arm_group_label>Co-trimoxazole 20</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 15 years

          2. Culture-confirmed melioidosis

          3. Currently on oral co-trimoxazole for 12(+2) weeks without any clinical evidence of
             active melioidosis

          4. High likelihood of completing at least 6 months follow up

          5. Willingness to participate in the study and written, informed consent obtained from
             the patient

        Exclusion Criteria:

          1. Pregnancy or breast feeding

          2. Contraindications to TMP-SMX: G6PD, severe adverse reactions grade 3-4 occurring
             during first 12 weeks of treatment

          3. Relapse melioidosis with at least 2 year symptom free period from last episode
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siriluck Anunnatsiri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Khon Kaen Univerisity</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Siriluck Anunnatsiri, MD</last_name>
    <phone>+6643 363 664</phone>
    <email>asiril@kku.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>Khon Kaen Univerisity</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siriluck Anunnatsiri, MD</last_name>
      <phone>+6643 363 664</phone>
    </contact>
    <investigator>
      <last_name>Siriluck Anunnatsiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2011</study_first_submitted>
  <study_first_submitted_qc>August 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2011</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Siriluck Anunnatsiri</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Meliodosis</keyword>
  <keyword>Co-trimoxazole</keyword>
  <keyword>Relapse</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

